Helping mothers and babies, from conception to birth
At Ferring, we are committed to helping people become parents and to keeping mothers and babies healthy, from conception to birth. Over one third of our research and development investment goes towards finding innovative treatments in reproductive medicine and maternal health. We are also passionate about making a difference to people’s health and quality of life through our work in gastroenterology and orthopaedics.
Believing in the power of research
Each of us at Ferring contribute to providing innovative solutions to help people live better lives. We devote significant research and development investment to new therapeutics, life cycle management and next generation healthcare solutions.
At Ferring Pharmaceuticals we highly value an attractive working environment that motivates our employees and stimulates the creative abilities and initiative of both individuals and teams. With over 6,000 employees in 56 countries, we are able to draw upon a large multicultural setting to enrich the work of our staff on all levels.
Helping people live better lives
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and orthopaedics. Ferring has been developing treatments for mothers and babies for over 50 years.
Ferring Receives U.S. FDA Approval for REBYOTA™ (fecal microbiota, live-jslm) – A Novel First-in-Class Microbiota-Based Live Biotherapeutic-
Ferring’s novel first-in-class REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treat...
Ferring Appreciates Ongoing Support from New Jersey and Minnesota as Both States Issue Proclamations Recognizing November as C. Difficile Infection Awareness Month-
Parsippany, NJ, USA – November 28, 2022 – Ferring Pharmaceuticals appreciates the continued support from New Jersey and Minnesota as both states recognize November as Clostridioides difficile (C. d...
Investigational RBX2660 showed statistically significant treatment success at reducing CDI recurrence at eight weeks compared to placebo at eight weeks In the study, RBX2660 was well tolerated with...